SCHEDULE: RA Capital Management Boosts Stake in Cidara Therapeutics to 15.8% Following $100 Million Public Offering Investment

RA Capital Management and its affiliates have significantly increased their beneficial ownership in Cidara Therapeutics, Inc. to 15.8% of outstanding common stock after investing nearly $100 million in a recent public offering.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13D regarding their beneficial ownership in Cidara Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 3,365,523 shares of common stock, representing 15.8% of the outstanding common stock.
• This percentage is based on 21,356,877 shares of common stock outstanding as of June 26, 2025.
• On June 26, 2025, RA Capital Healthcare Fund, L.P. purchased 2,272,727 shares of common stock at $44.00 per share from the underwriters of Cidara Therapeutics' public offering.
• The aggregate purchase price for this acquisition was $99,999,988, which was funded by the Fund's working capital.
• RA Capital Healthcare Fund, L.P. also holds Series A preferred stock convertible for up to 6,296,920 shares and pre-funded warrants exercisable for up to 1,286,786 shares.
• Conversion of the preferred stock and exercise of the pre-funded warrants are currently subject to "Beneficial Ownership Blockers," which preclude conversion or exercise if the Fund's ownership, together with affiliates, would exceed 9.99% of the common stock outstanding.

Sentiment

Score: 7

Explanation: The document reports a substantial investment by a major institutional investor, indicating strong confidence in the company. While there are beneficial ownership blockers, the overall tone is positive due to the significant capital infusion and increased stake.

Positives

• A significant investment of nearly $100 million by a major healthcare-focused fund like RA Capital indicates strong confidence in Cidara Therapeutics' future prospects.
• The acquisition of 2,272,727 shares at $44.00 per share from a public offering suggests a strategic long-term interest in the company.
• RA Capital Healthcare Fund, L.P. holds additional convertible preferred stock and pre-funded warrants, representing a substantial potential for further equity conversion, although currently limited by beneficial ownership blockers.

Negatives

• The presence of "Beneficial Ownership Blockers" limits the immediate conversion of preferred stock and pre-funded warrants, restricting RA Capital's ability to increase its direct common stock holdings beyond the reported 15.8% through these instruments.

Risks

• The "Beneficial Ownership Blockers" on preferred stock and pre-funded warrants limit the immediate conversion of these securities into common stock, which could affect RA Capital's liquidity or strategic flexibility regarding its investment in Cidara Therapeutics.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the current beneficial ownership and recent transaction details. The continued holding of convertible preferred stock and pre-funded warrants, despite current conversion blockers, suggests a potential for increased ownership in the future if the blockers are removed or the outstanding share count increases significantly.

Industry Context

This filing reflects a significant investment by a specialized healthcare fund, RA Capital, into a biotechnology company, Cidara Therapeutics. Such investments are common in the biotech sector, where institutional investors often take substantial stakes to support drug development and commercialization efforts. The public offering indicates Cidara Therapeutics is raising capital, a frequent occurrence for biotech firms requiring funds for research and development and clinical trials.

Stakeholder Impact

• Shareholders: The increased stake by a significant institutional investor like RA Capital could be viewed positively, potentially signaling confidence and stability. The public offering itself would dilute existing shareholders but also provides capital for the company's operations.
• Creditors: The capital raise from the public offering strengthens the company's financial position, potentially reducing credit risk.

Key Dates

Keywords

Cidara Therapeutics, RA Capital Management, Schedule 13D, Beneficial Ownership, Public Offering, Investment, Healthcare Fund, Common Stock, Preferred Stock, Warrants, SEC Filing